Bristol-Myers Squibb Company (BMY) vs Eli Lilly and Company (LLY)
A side-by-side comparison of Bristol-Myers Squibb Company and Eli Lilly and Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.60HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
LLY
Eli Lilly and Company
$1,222.61HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
Total return — BMY vs LLY
growth of $100 · dividends reinvested · last 30yBMY +735.9%LLY +8631.2%LLY compounded faster
Log scale — wide-divergence pair
BMY LLY
BMY vs LLY: by the numbers
- •LLY is the larger company ($1.15T vs $129.88B market cap).
- •BMY trades at the lower trailing earnings multiple (17.57 vs 42.54 P/E), one valuation lens rather than an overall verdict.
- •LLY converts more revenue to profit (34.98% vs 15.01% net margin).
- •LLY grew revenue faster over the past five years (23.17% vs 2.52% CAGR).
- •BMY pays the higher dividend yield (4.00% vs 0.54%).
Metrics side by side
Valuation
| Metric | BMY | LLY |
|---|---|---|
| P/E ratio | 17.57 | 42.54 |
| Forward P/E | 9.86 | 34.10 |
| P/S ratio | 2.64 | 14.85 |
| P/B ratio | 6.37 | 34.39 |
| PEG ratio | 1.87 | 0.49 |
| EV / EBITDA | 10.34 | 31.98 |
| FCF yield | 9.31% | 1.27% |
Profitability
| Metric | BMY | LLY |
|---|---|---|
| Gross margin | 68.75% | 83.51% |
| Operating margin | 25.67% | 45.87% |
| Net margin | 15.01% | 34.98% |
| ROE | 36.25% | 81.01% |
| ROIC | 13.90% | 30.20% |
Dividends
| Metric | BMY | LLY |
|---|---|---|
| Dividend yield | 4.00% | 0.54% |
| Payout ratio | 72.25% | 28.09% |
Growth (annualized)
| Metric | BMY | LLY |
|---|---|---|
| Revenue CAGR (5Y) | 2.52% | 23.17% |
| EPS CAGR (5Y) | 9.38% | 28.88% |
| FCF CAGR (5Y) | -2.50% | 19.54% |
| Total return CAGR (5Y) | 2.73% | 38.81% |
Frequently asked
- Which has the lower trailing P/E, BMY or LLY?
- BMY has the lower trailing P/E: BMY trades at 17.57 and LLY at 42.54. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or LLY?
- Over the past five years, LLY grew revenue faster — BMY at a 2.52% CAGR versus LLY at 23.17%.
- Does BMY or LLY pay a bigger dividend?
- BMY yields 4.00% and LLY yields 0.54% based on trailing dividends and the latest price.
- Is BMY or LLY more profitable?
- LLY runs the higher net margin — BMY at 15.01% versus LLY at 34.98%.
- How have BMY and LLY total returns compared?
- Over the past 10 years, BMY delivered 2.02% and LLY delivered 32.66% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioEli Lilly and P/E ratioBristol-Myers Squibb dividend yieldEli Lilly and dividend yieldBristol-Myers Squibb ROEEli Lilly and ROEBristol-Myers Squibb operating marginEli Lilly and operating marginBristol-Myers Squibb revenue growthEli Lilly and revenue growthBristol-Myers Squibb free cash flowEli Lilly and free cash flow
Bristol-Myers Squibb & Eli Lilly and appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.